Detalhe da pesquisa
1.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Cell
; 170(6): 1109-1119.e10, 2017 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28886381
2.
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Cell
; 174(4): 1031-1032, 2018 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30096300
3.
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Lancet
; 399(10336): 1718-1729, 2022 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35367007
4.
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Lancet Oncol
; 21(1): 121-133, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31812554
5.
Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings.
Qual Life Res
; 29(10): 2651-2660, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32405921
6.
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Lancet Oncol
; 20(8): 1083-1097, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31221619
7.
Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices.
Future Oncol
; 15(5): 459-471, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30251550
8.
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Pediatr Blood Cancer
; 65(7): e27023, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29603591
9.
MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state.
Genes Dev
; 23(6): 694-707, 2009 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19299559
10.
Assessment of palindromes as platforms for DNA amplification in breast cancer.
Genome Res
; 22(2): 232-45, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21752925
11.
Homology-mediated end-capping as a primary step of sister chromatid fusion in the breakage-fusion-bridge cycles.
Nucleic Acids Res
; 41(21): 9732-40, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23975201
12.
DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences.
Proc Natl Acad Sci U S A
; 107(1): 234-9, 2010 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-19966297
13.
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
J Clin Oncol
; 41(1): 75-85, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35867951
14.
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
J Clin Oncol
; 41(3): 528-540, 2023 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35998300
15.
Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases.
Front Oncol
; 12: 1025664, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36568199
16.
Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review.
Cancers (Basel)
; 14(24)2022 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36551594
17.
Current Treatment Approaches and Global Consensus Guidelines for Brain Metastases in Melanoma.
Front Oncol
; 12: 885472, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35600355
18.
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study.
Front Immunol
; 13: 882471, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36304457
19.
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
Eur J Cancer
; 160: 1-11, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34801354
20.
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
Eur J Cancer
; 157: 391-402, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34571336